Acute flares in chronic hepatitis B: The natural and unnatural history of an immunologically mediated liver disease

Gastroenterology

Volumn 120, Issue 4, 2001, Pages 1009-1022

  Perrillo, R P ^a  

^a OCHSNER CLINIC FOUNDATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT; CORTICOSTEROID; IMMUNOSUPPRESSIVE AGENT; INTERFERON; LAMIVUDINE; NUCLEOSIDE ANALOG; PREDNISONE;

CANCER CHEMOTHERAPY; CHRONIC LIVER DISEASE; CORTICOSTEROID THERAPY; DISEASE EXACERBATION; DRUG WITHDRAWAL; HEPATITIS B; HUMAN; IMMUNOPATHOGENESIS; IMMUNOSUPPRESSIVE TREATMENT; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; REVIEW; VIRUS GENOME; VIRUS REACTIVATION; VIRUS REPLICATION;

EID: 0035123958     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/gast.2001.22461     Document Type: Article

References (124)

1. Hepatitis B: An overview
2. Cytotoxic T cell responses in patients with chronic hepatitis B virus infection undergoing Hbe antigen/antibody seroconversion
3. HLA class I-restricted human cytotoxic T cells recognize endogenously synthesized hepatitis B virus nucleocapsid antigen
4. Intrahepatic distribution of hepatitis B surface and core antigens in chronic hepatitis B virus infection. Hepatocyte with cytoplasmic/membranous hepatitis B core antigen as a possible target for immune hepatocytolysis
5. Fluctuations in viremia, aminotransferases and IgM antibody to hepatitis B core antigen in chronic hepatitis B patients with disease exacerbations
6. Reactivation of chronic type B hepatitis presenting as acute viral hepatitis
7. Spontaneous clearance and reactivation of chronic hepatitis B virus infection among male homosexuals with chronic type B hepatitis
8. Reactivation of chronic hepatitis B virus infection
9. Symptomatic reactivation of hepatitis B in pregnancy
10. Acute exacerbations of chronic type B hepatitis are accompanied by increased T cell responses to hepatitis B core and e antigens. Implications for hepatitis B e antigen seroconversion
11. Comparative immunogenicity of hepatitis B virus core and E antigens
12. Immunohistochemical studies on intrahepatic lymphocyte infiltrates in chronic type B hepatitis, with special emphasis on the activation status of the lymphocytes
13. Cytolytic T-cell cytotoxicity is mediated through perforin and Fas lytic pathways
14. Natural history of chronic type B hepatitis
15. Spontaneous reactivation of chronic hepatitis B virus infection
16. Natural history of acute hepatitis B surface antigen-positive hepatitis in Greek adults
17. Evolving concepts of the clinical and serologic consequences of hepatitis B virus infection
18. Pathogenesis and clinical significance of spontaneous exacerbations and remissions in chronic hepatitis B virus infection
19. Clinical course of spontaneous reactivation of hepatitis B virus infection in patients with chronic hepatitis B
20. Spontaneous reactivation in chronic hepatitis B: Patterns and natural history
21. Long-term outcome of chronic type B hepatitis in patients who acquire hepatitis B virus infection in childhood
22. Acute exacerbation in hepatitis B e antigen positive chronic type B hepatitis. A clinicopathological study
23. Spontaneous hepatitis B e antigen to antibody seroconversion and reversion in Chinese patients with chronic hepatitis B virus infection
24. Monitoring of antiviral therapy with quantitative evaluation of Hbeag: A comparison to HBV DNA testing
25. Hepatitis viruses under immunosuppressive agents
26. Reactivation of chronic hepatitis B virus infection by cancer chemotherapy
27. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study
28. Massive hepatic necrosis after chemotherapy withdrawal in a hepatitis B virus carrier
29. Serial studies of hepatitis-associated antigen and antibody in patients receiving antitumor chemotherapy for myeloproliferative and lymphoproliferative disorders
30. Fulminant hepatic failure in leukaemia and choriocarcinoma related to withdrawal of cytotoxic drug therapy
31. Fatal reactivation of chronic hepatitis B virus infection following withdrawal of chemotherapy in lymphoma patients
32. Prevalence of hepatitis B virus marker positivity and evolution of hepatitis B virus profile, during chemotherapy, in patients with solid tumors
33. Reactivation of hepatitis B but not hepatitis C in patients with malignant lymphoma and immunosuppressive therapy. A prospective study in 305 patients
34. Hepatitis B infection in patients with lymphomas
35. Chemotherapy and bone marrow transplantation for cancer patients who are also chronic hepatitis B carriers: A review of the problem
36. Reactivation of hepatitis B after transplantation operations
37. Fulminant hepatitis due to reactivation of chronic hepatitis B virus infection after allogeneic bone marrow transplantation
38. Orthotopic liver transplantation for patients with hepatitis B virus-related liver disease
39. Redevelopment of hepatitis B surface antigen after renal transplantation
40. Reactivation of hepatitis B after transplantation in patients with pre-existing anti-hepatitis B surface antigen antibodies: Report on three cases and review of the literature
41. Recurrence of hepatitis B after single lung transplantation
42. Serum and liver hepatitis B virus DNA in chronic hepatitis B after sustained loss of surface antigen
43. Hepatitis B virus DNA in peripheral-blood mononuclear cells in chronic hepatitis B after Hbsag clearance
44. Hepatitis B virus replication in diverse cell types during chronic hepatitis B virus infection
45. Hepatic events after bone marrow transplantation in patients with hepatitis B infection: A case controlled study
46. Hepatic histological findings after transplantation for chronic hepatitis B virus infection, including a unique pattern of fibrosing cholestatic hepatitis
47. Increased hepatocyte expression of hepatitis B virus transcription in patients with features of fibrosing cholestatic hepatitis
48. Glucocorticoid stimulates hepatitis B viral gene expression in cultured human hepatoma cells
49. Serum levels of hepatitis B surface and core antigens during immunosuppressive treatment of Hbsag-positive chronic active hepatitis
50. Effects of short-term, high-dose prednisone treatment of patients with Hbsag-positive chronic active hepatitis
51. Effects of immunosuppressive therapy on viral markers in chronic active hepatitis B
52. Interferon therapy of hepatitis B
53. Treatment of chronic hepatitis B with lamivudine in renal transplant recipients
54. Successful treatment with lamivudine for fulminant reactivated hepatitis B infection following intensive therapy for high-grade non-Hodgkin's lymphoma
55. Recovery form life-threatening, corticosteroid-responsive, chemotherapy-related reactivation of hepatitis B associated with lamivudine therapy
56. Prevention of hepatitis B flare-up during chemotherapy using lamivudine: Case report and review of the literature
57. Case report: Lamivudine therapy for submassive hepatic necrosis due to reactivation of hepatitis B following chemotherapy
58. Lamivudine therapy for chemotherapy-induced reactivation of hepatitis B virus infection
59. Lamivudine in the treatment of hepatitis B virus reactivation during cytotoxic chemotherapy
60. Lamivudine allows completion of chemotherapy in lymphoma patients with hepatitis B reactivation
61. Use of famciclovir to prevent HBV reactivation in Hbsag-positive recipients after allogeneic bone marrow transplantation
62. The interferon system in acute and chronic viral hepatitis
63. Loss of Hbsag with interferon therapy in chronic hepatitis B virus infection
64. A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B
65. Interferon alfa for patients with clinically apparent cirrhosis due to chronic hepatitis B
66. Low-dose, titratable interferon alfa in decompensated liver disease caused by chronic infection with hepatitis B virus
67. Fatal exacerbation of chronic hepatitis B induced by recombinant alpha-interferon
68. Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B
69. Randomized controlled trial of adenine arabinoside monophosphate for chronic type B hepatitis
70. Lamivudine as initial treatment for chronic hepatitis B in the United States
71. Evolution of hepatitis B virus polymerase gene sequence during famciclovir therapy for chronic hepatitis B
72. Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B
73. Cell-mediated immune responses and loss of hepatitis B e-antigen (Hbeag) during successful lamivudine and famciclovir combination therapy for chronic replicating hepatitis B virus infection
74. Hepatitis B reactivation after lamivudine
75. Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy
76. Reactivation of hepatitis B in a long-term anti-Hbs-positive patient with AIDS following lamivudine withdrawal
77. Comparative efficacy of adenine arabinoside 5′ monophosphate and prednisone withdrawal followed by adenine arabinoside 5′ monophosphate in the treatment of chronic active hepatitis type B
78. Prednisolone withdrawal therapy enhances the effect of human lymphoblastoid interferon in chronic hepatitis B
79. Case report: Dramatic response to lamivudine therapy following corticosteroid priming in chronic hepatitis B
80. Prednisolone priming enhances TH1 response and efficacy of subsequent lamivudine therapy in patients with chronic hepatitis B
81. Effects of immunosuppressive therapy with prednisolone on B and T lymphocyte function in patients with chronic type B hepatitis
82. Antiviral therapy of chronic hepatitis B: Past, present, and future
83. Severe clinical rebound upon withdrawal of corticosteroid before interferon therapy: Incidence and risk factors
84. Severe hepatic failure after ARA-A prednisolone for chronic type B hepatitis
85. Exacerbation of chronic active hepatitis type B after short-term corticosteroid therapy resulting in fatal liver failure
86. Wild-type and e antigen-minus hepatitis B viruses and course of chronic hepatitis
87. Is a function of the secreted hepatitis B e antigen to induce immunologic tolerance in utero?
88. Pre-core/core gene mutants of hepatitis B virus: Pathogenetic implications
89. Low level wild-type and pre-core mutant hepatitis B viruses and Hbeag negative reactivation of chronic hepatitis B
90. Clinical relevance of hepatitis B viral mutations
91. Mutation of nucleoside 1,762 in the core promoter region during hepatitis B e seroconversion and its relation to liver damage in hepatitis B e antigen carriers
92. Hepatitis B virus core promoter mutations in children with multiple anti-Hbe/Hbeag reactivations result in enhanced promoter activity
93. Clinical and molecular virological differences between fulminant hepatic failures following acute and chronic infection with hepatitis B virus
94. Hepatitis B virus reactivation in patients undergoing cytotoxic chemotherapy for solid tumours: Precore/core mutations may play an important role
95. Two sensitive PCR-based methods for detection of hepatitis B virus variants associated with reduced susceptibility to lamivudine
96. Multicenter study of lamivudine therapy for hepatitis B after liver transplantation
97. Hepatitis B mutants associated with 3TC and famciclovir administration are replication defective
98. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy
99. Clearance of the original hepatitis B virus YMDD-motif mutants with emergence of distinct lamivudine-resistant mutants during prolonged lamivudine therapy
100. Hepatitis A infection in chronic carriers of hepatitis B virus
101. Fulminant hepatitis associated with hepatitis A virus superinfection in patients with chronic hepatitis C
102. Hepatitis A infection in chronic carriers of hepatitis B virus
103. Double infections with hepatitis A and B viruses
104. Clinical spectrum and natural history of viral hepatitis A in a 1988 Shanghai epidemic
105. Influence of delta infection on severity of hepatitis B
106. Hepatitis delta: An overview
107. Fulminant hepatic failure in acute hepatitis C: Increased risk in chronic carriers of hepatitis B virus
108. Displacement of hepatitis B virus by hepatitis C virus as the cause of continuing chronic hepatitis
109. The etiology of acute hepatitis superimposed upon previously unrecognized asymptomatic Hbsag carriers
110. Interference with viral multiplication
111. Is hepatitis A more severe in patients with chronic hepatitis B and other chronic liver diseases?
112. The significance of antibody to hepatitis C virus in patients with chronic hepatitis B
113. Delta-infection and suppression of hepatitis B virus replication in chronic HbsAg carriers
114. Concurrent hepatitis C virus and hepatitis delta virus superinfection in patients with chronic hepatitis B virus infection
115. Role of hepatitis C virus infection in spontaneous hepatitis B surface antigen clearance during chronic hepatitis B virus infection
116. Reactivation of hepatitis B virus infection induced by interferon (IFN) in Hbsag-positive, antiHCV-positive patients
117. Chronic hepatitis B in asymptomatic homosexual men with antibody to the human immunodeficiency virus
118. The influence of HTLV-III infection on the natural history of hepatitis B virus infection in male homosexual HbsAg carriers
119. The influence of human immunodeficiency virus infection on acute and chronic HbsAg-positive hepatitis
120. Restoration of immunity to chronic hepatitis B infection in an HIV-infected patient on protease inhibitor
121. Reactivation of hepatitis B in patients with human immunodeficiency virus infection treated with combination antiretroviral therapy
122. Chronic active hepatitis B exacerbations in human immunodeficiency virus-infected patients following development of resistance to or withdrawal of lamivudine